Addressing Insulin Injection Technique: A Follow-up Study of Canadian Patients with Diabetes.

INTRODUCTION: Proper insulin injection technique is important for optimal glycaemic control, yet patients with diabetes often inject insulin incorrectly. Previous studies identified common errors in insulin injection in Canada, and this article seeks to evaluate the current insulin injection technique practices among patients and explore the effectiveness of feedback and education in improving their technique. METHODS: The study recruited 147 patients and 16 physicians across Canada to gather insights into current insulin injection practices and education gaps. Eligible patients were people living with diabetes who inject insulin using an insulin pen and pen needles. Eligible physicians, who were unsupported by diabetes educators, completed a practice assessment survey and selected 10 eligible patients to complete a baseline assessment survey. During the patient visit, if an error in the patient's technique was identified, a pop-up knowledge transfer (KT) prompt would appear, providing feedback and information on best practices at the point of care. Follow-up surveys were completed 1-3 months later. RESULTS: Physicians reported facing barriers to providing education and feedback, including lack of time and personnel, and lack of effective educational material. Patients demonstrated modest improvements in some injection technique domains at their follow-up visit, including injection force factors, time the needle was held in the skin, pen needle reuse, injection area size, and injection angle. The most common initial mistakes by patients were selecting an area smaller than recommended and not paying attention to the injection force. At the second visit, patients reduced an average of one error in their injection technique. CONCLUSION: Results showed that basic feedback by their physician during one visit could exert moderate improvements on patients' injection technique. Proper injection technique is critical for diabetes management, and incorporating targeted ongoing education and support can significantly enhance physician practices, ultimately reducing risks and improving outcomes.

Vacation ease: travelling with an insulin pump.

BACKGROUND: Vacation travel is a welcome retreat from our everyday world. Whether the trip is trekking in Nepal, a ski vacation in the western Rockies or a beach holiday to the Caribbean, the insulin pump is a constant companion for many people with diabetes. As a healthcare professional assisting individuals in their travel plans, we can contribute to the success of their trip by encouraging early preparation and by sharing practical and timely tips. PURPOSE: To provide current information and practical insights for healthcare professionals (HCP) who are counseling patients with diabetes travelling with an insulin pump. LIMITATIONS: There are numerous suggestions for all patients with diabetes who travel. This article will focus on travel recommendations specific to the pump user. Due to the lack of research in this area the information shared is based on evidence where possible and otherwise patient experience. CONCLUSION: Insulin pump users can enjoy any type of vacation travel. Certain destinations require more preparation than others but regardless of the choice of venue, preplanning in collaboration with a knowledgeable health care provider can contribute to a successful experience.

Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.

Here, we discuss certain practical issues related to use of insulin degludec, a new long-acting basal insulin analogue. Degludec provides uniform ("peakless") action that extends over more than 24 hours and is highly consistent from dose to dose. Like the 2 previously available basal analogues (detemir and glargine), degludec is expected to simplify dose adjustment and enable patients to reach their glycemic targets with reduced risk of hypoglycemia. Phase 3 clinical trials involving type 1 and type 2 diabetes have demonstrated that degludec was noninferior to glargine in allowing patients to reach a target glycated hemoglobin (A1C) of 7%, and nocturnal hypoglycemia occurred significantly less frequently with degludec. In addition, when dosing intervals vary substantially from day to day, degludec continues to be effective and to maintain a low rate of nocturnal hypoglycemia. Degludec thus has the potential to reduce risk of nocturnal hypoglycemia, to enhance the flexibility of the dosing schedule and to improve patient and caregiver confidence in the stability of glycemic control. A dedicated injector, the FlexTouch prefilled pen, containing degludec 200 units/mL, will be recommended for most patients with type 2 diabetes. Degludec will also be available as 100 units/mL cartridges, to be used in the NovoPen 4 by patients requiring smaller basal insulin doses, including most patients with type 1 diabetes.